+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06940388

Phase II Randomized Study of Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer

Led by brenner baruch · Updated on 2025-07-24

134

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the addition of immunotherapy with tislelizumab to the current most effective treatment approach for locally advanced rectal cancer LARC. This phase II randomized controlled trial aims to assess whether combining tislelizumab with total neoadjuvant therapy TNT can improve long-term, surgery-free survival over standard TNT alone. The study focuses on new treatment combinations designed to enhance the immune response and potentially reduce the need for major surgery called total mesorectal excision TME. Participants will be randomly assigned to one of two groups. The experimental group receives 6 weeks of capecitabine-based chemoradiotherapy CRT, followed by 16 weeks of chemoimmunotherapy with tislelizumab and mFOLFOX6 chemotherapy every two weeks. The control group receives the same CRT followed by 16 weeks of mFOLFOX6 chemotherapy alone, also every two weeks. After treatment, patients will be evaluated around 8 weeks later to check tumor response and decide further management, including close monitoring or surgery if needed. Throughout the study, participants will undergo regular assessments including imaging and clinical exams to monitor tumor status and side effects. Researchers will track outcomes such as 3-year surgery-free survival, disease-free survival, overall survival, and safety events. Follow-up will continue according to standard guidelines to observe long-term effects. The total participation time spans multiple years to capture these outcomes and ensure careful monitoring of health and treatment effects.

CONDITIONS

Brief Title

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

Research Team

B

Baruch Brenner, M.D

A

Ayelet Rosenberg Ayal, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here